Abstract Library

#4239 Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

Introduction: There is international evidence supporting nurse-led services for people with chronic diseases in reducing hospitalisations, symptom improvement and lifestyle, and patient satisfaction. Patients with NET often have high symptoms burden and psychosocial distress in the context of indolent disease. Our centre recently implemented a (NLC) to provide complex care support for patients with NET.

Conference:

Presenting Author:

Authors: Wakelin K, Michael M, Kong G, Rogers M, Natkunarajah N,

Keywords: Nurse-led care, Multidisciplinary care, Supportive care, Symptom management, Patient support,

#3839 The impact of the COVID-19 pandemic on neuroendocrine tumor (NET) service recovery and patient perceptions in Sheffield NET Centre UK – A quantitative and qualitative analysis 2017-2021

Introduction: The COVID-19 pandemic has affected the delivery of NET services and patient care. To assess the evolution of NET services during and peri-pandemic, we retrospectively analysed NET services and patient perceptions between 2017-2021.

Conference:

Presenting Author: Munir A

Authors: Munir A, Dabke T, Finnen J,

Keywords: COVID-19, NET, Service, Patient Satisfaction, Therapy, Psychology,

#3788 Patient initiated follow-up for surgically resected neuroendocrine tumor patients using a digital system – My Medical Record

Introduction: Patient Initiated Follow Up (PIFU) is well established in this regional cancer centre, it allows patients to contact a cancer specialist team based on symptoms and individual circumstances. Patients are empowered to manage follow-up remotely, undertaking cancer surveillance tests and accessing results through the digital system MyMedicalRecord (MyMR).

Conference:

Presenting Author:

Authors: Ramsey E, Marsh C, Jarvis E, Armstrong T, Knight J,

Keywords: surveillance, Patient-initiated follow-up, neuroendocrine tumor, follow-up,

#3628 Retrospective survival analysis of patients with small bowel neuroendocrine tumors (NETs) and analysis of patient satisfaction post covid pandemic in the Sheffield European Neuroendocrine Tumor Society (ENETS) Centre of Excellence (COE)

Introduction: Small bowel NETs are the commonest primary malignancies of the small bowel. Incidence is increasing, but it is often still diagnosed at a late stage. The effects of COVID-19 may have affected patient satisfaction. Reported survival is quoted at 90% at 1 year and 70% at 5 years for all stages.

Conference:

Presenting Author:

Authors: Kwok W, Finnen J, Munir A,

Keywords: Neuroendocrine, cell, research, Neuroendocrine tumor, Survival analysis, patient satisfaction,

#3500 HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs)

Introduction: LAN is a long-term treatment for NETs, delivered in a ready-to-use syringe by monthly, deep subcutaneous injection. LAN PSPs aim to assist patients receiving their treatment at home, reducing both travel burden and the current risk of COVID-19 exposure. Furthermore, after training patients on stable dose can administer LAN independently (self or non-healthcare professional), where approved.

Conference:

Presenting Author: Hernando J

Authors: Hernando J, Kolarova T, Verslype C, Kaltsas G, Houchard A,

Keywords: neuroendocrine tumor, patient satisfaction, patient support programme, patient survey, lanreotide autogel,